Skip to main content
OpenTrials
Completed

NCT Number: NCT04044898

Pharmacokinetics and Safety of ALA in Acne Vulgaris

This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Huashan Hospital

Shanghai, Shanghai Municipality, 200040, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female subjects between 18 and 45 years of age (all subjects are male in pilot study);
  • Diagnosis of moderate to severe facial acne vulgaris by the clinician according to the Pillsbury International Improvement Classification III-IV criteria;
  • Body weight≥50 kg, body mass index (BMI) ≥19 and ≤28 kg/m2；
  • Subjects (including male subjects) voluntarily adopt effective physical contraception from 14 days prior to the use of the study drug to 1 month after the end of the study, and have no fertility or donation of sperm/egg plan;
  • Subjects voluntarily sign informed consent forms after being informed of the study procedures，requirements and possible adverse reactions of the study drug.

Exclusion criteria

  • Suffer from allergic diseases ，suspect or known to have porphyrin disease or known to be allergic to test medication and/or porphyrin， or allergic persons (such as allergies to two or more drugs, food or pollen);
  • Allergies to visible light
  • Secondary acne patients, such as acne caused by occupational acne and corticosteroids.
  • Suffering from malignant tumors and suffering from diseases such as heart, endocrine, blood, liver, immunity, metabolism, urinary system, lungs, nervous system, rheumatism/joint, mental, kidney, etc led the researchers to believe that the subject is not suitable for participating in this study
  • Have been treated with systemic Vitamin A acid drugs therapy within 2 months before the study and/or antibiotics or hormonal drugs within 4 weeks before the study
  • Used local topical vitamin A acid drugs within the 4 weeks before the study or patients with topical antibiotics, glucocorticoid and other topical treatment of acne drugs within the 2 weeks before the study
  • Vaccination within 4 weeks prior to the use of the study drug;
  • Severe external injuries were suffered within the first 3 months (90 days) prior to the use of the study drug, or Patients who have undergone surgical treatment may significantly affect the process of studying drugs in vivo or safety assessment;
  • Taked clinical trial drugs within 3 months (90 days) prior to the use of the study drug, or be participating in or plan to participate in other clinical trials during the study period.
  • Drinking alcohol regularly within 3 months (90 days) prior to the use of the study drug (≥3 times a week, and the average drink is equivalent to 50° white wine ≥200 mL) or can not quit drinking during the study, or alcohol breath test positive
  • Smoking cigarettes (more than 10 cigarettes or equivalent of tobacco per day) within 3 months (90 days) prior to the use of the study drug or those who cannot quit smoking during the study;
  • Blood loss/blood donation more than 300 mL (except for female physiological blood loss), blood transfusion or blood product use within 3 months (90 days) prior to the use of the study drug, or plan to be blood donors during the study period or 1 month after the end of the study l (30 days) )
  • Consumed excessively daily tea, coffee or caffeinated beverages (up to 8 cups per day, 200 mL per cup) within 1 month (30 days) prior to the use of the study drug;
  • Drinks or food intake excessive of alcohol or caffeine (coffee, tea, cola, chocolate, etc.) within 48 hours prior to the use of the study drug ;
  • Have a history of drug abuse or positive drug abuse screening;
  • Hepatitis B surface antigen or hepatitis C virus antibody or treponema pallidum antibody positive or HIV Screening positive;
  • Physical examination (except acne), Vital Signs, laboratory examination (blood routine, urine routine, liver function, renal function, fasting blood glucose, blood lipids, etc).and 12 lead ECG results were judged to be abnormal and clinically significant by clinicians
  • Pregnant or lactating female; blood or urine pregnancy test positive
  • Have a history of blood or Needles fainting, or difficulty in collecting blood
  • Unable to complete the study for other reasons or Researchers believe that those who should not be included;
  • Researchers and their relatives including spouses and children will be not allowed to participate in this study.

Treatment and study plan

ALA 5%

Drug

prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose

ALA 10%

Drug

prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose

Primary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  2. Area Under the Curve [AUC]

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  3. Tmax

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  4. Half-life Time [T1/2]

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  5. Clearance [CL]

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  6. Apparent Volume of Distribution [Vd]

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  7. Maximum Plasma Concentration [Cmax](after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  8. Area Under the Curve [AUC](after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  9. Tmax(after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  10. Half-life Time [T1/2](after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  11. Clearance [CL](after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  12. Apparent Volume of Distribution [Vd](after deduction of background)

    Time frame: 24 hours postdose

    pharmacokinetic parameter

  13. Incidence of adverse events

    Time frame: 2 days postdose

    Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses

Sponsors and collaborators

Lead sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Pharmacokinetics and Safety Study of Aminolevulinic Acid Hydrochloride Topical Powder in Subjects With Moderate to Severe Facial Acne Vulgaris.

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Aug 5, 2019
Registry last updated
Mar 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.